Is a Uric Acid Level of 500 µmol/L Considered High?

Is a serum uric acid level of 500 µmol/L considered elevated? Yes—this value exceeds the upper limit of the normal reference range for most adults. In clinical practice, normal serum uric acid concentrations typically fall between 208–428 µmol/L (3.5–7.2 mg/dL) in men and 155–357 µmol/L (2.6–6.0 mg/dL) in women. A level of 500 µmol/L (approximately 8.4 mg/dL) therefore represents hyperuricemia, regardless of sex.

While hyperuricemia itself is often asymptomatic, it is a well-established risk factor for gout, uric acid nephrolithiasis, and chronic kidney disease. Persistent elevation above 480 µmol/L (8.0 mg/dL) significantly increases the likelihood of monosodium urate crystal deposition in joints and soft tissues—potentially triggering acute gouty arthritis or tophaceous deposits. Additionally, epidemiologic studies associate sustained hyperuricemia with hypertension, insulin resistance, and cardiovascular morbidity, though causality remains under active investigation.

Clinical evaluation should not rely solely on a single uric acid measurement. Factors such as recent dietary intake (e.g., purine-rich foods or alcohol), dehydration, renal function, medications (e.g., diuretics, low-dose aspirin, or immunosuppressants), and comorbidities—including metabolic syndrome and chronic kidney disease—must be assessed. Confirmatory testing with repeat fasting serum uric acid measurement, along with renal function panels (creatinine, eGFR), urinalysis, and uric acid excretion studies when indicated, helps guide appropriate management.

Management strategies depend on symptom status and overall cardiovascular–renal risk profile. Asymptomatic hyperuricemia generally does not require pharmacologic intervention; lifestyle modifications—including weight optimization, reduced intake of fructose-sweetened beverages and red/organ meats, increased low-fat dairy consumption, and moderation of alcohol—are first-line recommendations. Pharmacologic urate-lowering therapy (e.g., allopurinol or febuxostat) is typically reserved for patients with recurrent gout, tophi, uric acid kidney stones, or rapidly declining renal function.